Shionogi Inc. President and CEO John Keller to Receive Innovation Award from NY American Chemical Society CME Group

Shionogi Inc. is the US subsidiary of Shionogi & Co. Ltd., a pharmaceutical company with headquarters in Osaka, Japan. For over 139 years, Shionogi has been dedicated to developing medicines that protect the health and well-being of patients worldwide. Addressing unmet medical needs and improving quality of life for patients and their families are what drives the company, its philosophy and its teams.

"Few companies of any size in the pharmaceutical sector have tripled in value in the last three years. This achievement is the result of Shionogi's dedication of innovation and focus on patients," Mr. George Rodriguez, Leadership Awards founder and CME Past Chair said. "Dr. Keller has led Shionogi's US subsidiary for 6 years, focusing on bringing the benefits of Shionogi's small molecule drug innovations to US patients, both through Shionogi Inc.'s own efforts and through the establishment of multiple creative collaborations."

Since joining Shionogi Inc. in 2010, Dr. Keller has played an instrumental role in establishing highly effective and efficient development and commercialization capabilities at Shionogi Inc. In this period, Shionogi obtained its first two US NDA approvals as a global organization, and Shionogi Inc. is now tightly focused on its science-based heritage and core therapeutic areas, including Infectious Disease and Pain/CNS.

"On behalf of the dedicated employees of Shionogi Inc. and Shionogi globally, I am delighted to be recognized by the business-focused topical group of the largest scientific society in the world and look forward to celebrating CME's 63 years of service at the prestigious Leadership Awards event," noted Dr. Keller.  

Dr. Keller joined Shionogi Inc. in July of 2010, as Executive Vice President, Corporate Development and Strategy, and was appointed as President and Chief Executive Officer, and as a member of the Shionogi Inc, Board of Directors, in April 2011. In April 2013, Dr. Keller was appointed as a Corporate Officer of Shionogi & Co. Ltd, and was promoted to Senior Executive Officer in April 2017.

Immediately prior to joining Shionogi, Dr. Keller was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, Dr. Keller served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, Dr. Keller had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development.  Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management and drug discovery research.  Dr. Keller is also President of the New York Pharma Forum and a Board member of ViiV Healthcare Ltd.

Dr. Keller holds a Ph.D. in microbiology from Rutgers University and a Bachelor degree in biology from Johns Hopkins University.

The other CME honorees on December 5 include Dr. David Skorton, Secretary of the Smithsonian Institution, and Mr. Christopher Pappas, Trinseo CEO. The CME Leadership Awards™ honors leaders with distinction in harnessing the transformative power of chemistry to advance humanity. Past honorees include Len Blavatnik (Access Industries), Charles Bolden (NASA), David Cote (Honeywell), Jean-Pierre Clamadieu (Solvay), Dr. Roy Vagelos (Regeneron, Merck), Erik Fyrwald (Univar), Jon M. Huntsman (Huntsman) and Andrew Liveris (Dow), among others. 

Dr. Allison Campbell, ACS President, will participate in the 2017 CME Leadership Awards™. Funds raised for the event will help advance exciting STEM programs including ACS Scholars and the first ACS-NASA Journey to Mars Symposium to be held on August 22-23, 2017 as part of ACS 254^th National Meeting in Washington, DC.

About Shionogi

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to bringing benefits to patients based on its corporate philosophy of "supplying the best possible medicine to protect the health and well-being of the patients we serve." Shionogi's research and development currently target two therapeutic areas: infectious diseases and pain/CNS disorders. For over 50 years, Shionogi has developed and commercialized innovative oral and parenteral anti-infectives. In addition, Shionogi is engaged in new research areas, such as obesity/geriatric metabolic disease and oncology/immunology. Contributing to the health and quality of life of patients around the world through development in these therapeutic areas is Shionogi's primary goal. For more details, please visit www.shionogi.co.jp/en/ . For more information on Shionogi Inc., the U.S.-based subsidiary of Shionogi & Co., Ltd., headquartered in Florham Park, NJ, USA, please visit www.shionogi.com . For more information on Shionogi Ltd., the UK-based subsidiary of Shionogi & Co. Ltd., headquartered in London, England, please visit www.shionogi.eu.

About CME

Established in 1954, the Chemical Marketing and Economics (CME) group of the American Chemical Society's New York Section, Inc. (ACS NY), organizes monthly luncheons in New York City where business and investment leaders share their insights on energy, materials and life science. A nonprofit organization established in 1876 and chartered by the U. S. Congress, the American Chemical Society (ACS) is the world's largest scientific society with over 150,000 members. www.cmeacs.org

SOURCE Shionogi

Related Links

http://www.shionogi.com